RHO and prostate cancer: NSC23766 is an early example discovered from virtual screening; it inhibits Rac-GEF interactions through binding to a groove located in Rac/GEF interface and does not interfere with interactions of Rho and CDC42 with their specific GEFs.337 NSC23766 inhibits proliferation, anchorage-independent growth, and invasion of the prostate cancer PC-3 cells.